Print
Email
Print Edition Stories
MHT's Emerging Technologies Forum: Health IT and the Cloud
MHT talks with Christopher Lambert of WPI Center for Neuroprosthetics
InfraReDx Inc., a Burlington-based medical device firm, has been granted clearance from the U.S. Food and Drug Administration to market its LipiScan IVUS Coronary Imaging System. The system is intended to be used by cardiologists for the purpose of identifying lipid core coronary plaques, linked to heart attacks after stenting.
With the FDA 510(k) clearance, InfraReDx noted in a press release today that it plans to commercially launch the coronary imaging system by the end of 2010, with additional plans to gain approval to launch the system in Europe in 2011.
The company noted in a press release that the LipiScan IVUS Coronary Imaging System is the “first cardiac catheter to combine intravascular ultrasound (IVUS) and near-infrared (NIR) spectroscopy.” Its NIR spectroscopy identifies the chemical content of the plaque, while the intravascular ultrasound gives doctors and image of the plaque and stent.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
